Paul A. Areas of expertise: Vaccines, Infectious disease. Locations: Main Building. He is the Maurice R. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a recipient of many awards including the J.
Offit has published more than papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC. For this achievement, Dr. In , Dr. In , he was elected to the board of trustees at the College of Physicians in Philadelphia, and in , he was elected to the American Association of Physicians and the American Academy of Arts and Sciences as well as being named as a Fellow for the Pediatric Infectious Diseases Society and the American Academy for the Advancement of Science.
Maurice R. Plotkin, Walter A. Orenstein, Paul A. Offit, Kathryn M. Edwards, and Elsevier Inc. Plotkin, S. Offit, and P. Pediatr Infect Dis J. Offit PA. Viral Immunol. Offit, P. Treatment with quadrivalent human papillomavirus vaccine for juvenile-onset recurrent respiratory papillomatosis: case report and review of the literature.
J Pedatr Infect Dis Soc ; doi The impact of access to immunization information on vaccine acceptance in three countries. PLOS One. A randomized trial to increase acceptance of childhood vaccines by vaccine-hesitant parents: a pilot study. Academic Pediatrics Feemster KA, Prasad P. Health care worker support of an influenza vaccine mandate at a large pediatric tertiary care hospital. Vaccine Effects of potency and composition of the multivalent human-bovine WC3 reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Safety and efficacy of pentavalent human-bovine WC3 reassortant rotavirus vaccine in preventing rotavirus gastroenteritis and associated healthcare contacts. Med Why are pharmaceutical companies gradually abandoning vaccines? Health Affairs Journal, Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI Different dose response patterns to virus surface proteins vp7 and vp4.
